Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. (BCLI) Revenue
Annual & quarterly revenue history · segment & region breakdown
BCLI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsBrainstorm Cell Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $-0.00B | -$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Brainstorm Cell Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Brainstorm Cell Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Brainstorm Cell Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BCLI revenue · 4 questionsBCLI's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Brainstorm Cell Therapeutics Inc. SEC filings · GAAP · Brainstorm Cell Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026